Wang HaiTao, Li BaoGuo, Zhang PengYu, Yao YanHong, Chang JiWu
Tumour Biol. 2014 Jan;35(1):595-601. doi: 10.1007/s13277-013-1083-6.
Liver metastasis from prostate cancer is uncommon and remains poorly understood. We computer searched the clinical records of all our patients registered into a database to identify patients that presented or developed liver metastases. A total of 27 prostate cancer patients with ultrasound or CT/MR imaging evidence of liver metastases were included in our analysis. The liver metastasis rate from metastatic prostate cancer was 4.29%. Eight (29.63%) patients had previously untreated, hormone-naive prostate cancer (synchronous liver metastases at diagnosis of prostate cancer), whereas 19 (70.37%) patients had already been diagnosed as having hormone-refractory prostate cancer. In the hormone-naive group, the median overall survival after liver metastases diagnosis was 38 months and half of the patients were still alive at the latest follow-up, whereas only 6 months in the hormone-refractory group (p = 0.003). High concentration of serum neuron-specific enolase and previous chemotherapy were associated with a significantly poor overall survival after liver metastases in the hormone-refractory group using Kaplan–Meier curves and logrank tests for univariate analysis.
前列腺癌肝转移并不常见，目前对其了解仍较少。我们通过计算机检索了登记在数据库中的所有患者的临床记录，以确定出现或发生肝转移的患者。共有27例经超声或CT/MR成像证实有肝转移的前列腺癌患者纳入我们的分析。转移性前列腺癌的肝转移率为4.29%。8例（29.63%）患者为未经治疗的激素初治前列腺癌（前列腺癌诊断时同步肝转移），而19例（70.37%）患者已被诊断为激素难治性前列腺癌。在激素初治组中，肝转移诊断后的中位总生存期为38个月，最新随访时半数患者仍存活，而激素难治性组仅为6个月（p = 0.003）。使用Kaplan–Meier曲线和对数秩检验进行单因素分析显示，激素难治性组中血清神经元特异性烯醇化酶浓度高和既往化疗与肝转移后的总生存期显著较差相关。
